Skip to main content
SpringerLink
Log in

Bone SPECT/CT in Oncology

  • Chapter
  • First Online:
Clinical Applications of SPECT-CT

  • 1651 Accesses

Abstract

Depending on the stage, prostate cancer generally metastasizes in the locoregional lymph nodes of the pelvis. Subsequently, tumor extension follows the lymphatic vessels to the retroperitoneal and paraaortal region or will disseminate into the bones, the lung, and the liver [1, 2]. Typically, prostate cancer generates osteoblastic bone metastases that are mainly located in the vertebral column (lumbar region), in the pelvis, and in the ribs [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Saitoh H, Hida M, Shimbo T, et al. Metastatic patterns of prostatic cancer. Cancer. 1984;54:3078–84.

    Article  PubMed  CAS  Google Scholar 

  2. De la Monte SM, Moore GW, Hutchins GM. Metastatic behaviour of prostate cancer. Cancer. 1986;58:985–93.

    Article  PubMed  Google Scholar 

  3. Catalona WJ, Smith DJ. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837–42.

    PubMed  CAS  Google Scholar 

  4. Ohori M, Goag JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994;152:1843–9.

    PubMed  CAS  Google Scholar 

  5. Epstein J, et al. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3586.

    Google Scholar 

  6. Perez CA, Hanks GE, Leibel SA, et al. Localized carcinoma of the prostate (stages T1, T2 and T3). Cancer. 1993;72:3156–73.

    Article  PubMed  CAS  Google Scholar 

  7. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–7.

    Article  PubMed  Google Scholar 

  8. Noldus J, Stamey TA. Limitations of serum PSA in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol. 1996;155:232–7.

    Article  PubMed  CAS  Google Scholar 

  9. Kelsey JL, Gammon MD. The epidemiology of breast cancer. Cancer. 1991;41:146–65. Berg JW, Hutter RV. Breast cancer. Cancer. 1995;75:257–69.

    CAS  Google Scholar 

  10. Possinger K, Große Y. Mammakarzinome und gynäkologische Tumoren. In: Wilmanns W, Huhn D, Wilms K, editors. Internistische Onkologie. Stuttgart: Thieme Verlag; 2000.

    Google Scholar 

  11. Spratt JS, Donegan WL. Cancer of the breast. Philadelphia: Saunders; 1979.

    Google Scholar 

  12. Tabar L, Grad A, Holmberg LH, et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet. 1985;1:829.

    Article  PubMed  CAS  Google Scholar 

  13. Koscielny SM, Tubiana M, Le MG, et al. Breast cancer. Relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer. 1984;49:709.

    Article  PubMed  CAS  Google Scholar 

  14. Foster Jr RS, Lang SP, Constanza MC, et al. Breast self-examination practices and breast cancer stage. N Engl J Med. 1978;299:265.

    Article  PubMed  Google Scholar 

  15. Miller AB, Baines CJ, To T, et al. Canada national breast screening study. Can Med Assoc J. 1992;147:1459–88.

    CAS  Google Scholar 

  16. Clark GM, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol. 1987;5:55–61.

    PubMed  CAS  Google Scholar 

  17. Come SE, Schnipper LE. Myelophtisisanemia and other aspects of bone marrow involvement. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases. Philadelphia: Lippincott; 1991. p. 761–6.

    Google Scholar 

  18. Kamby C, Bruun Rasmussen B, Kristensen B. Prognostic indicators of metastatic bone disease in human breast cancer. Cancer. 1991;68:2045–50.

    Article  PubMed  CAS  Google Scholar 

  19. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat. 1992;21:15–26.

    Article  PubMed  CAS  Google Scholar 

  20. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–63.

    Article  PubMed  CAS  Google Scholar 

  21. Noguchi S, Miyauchi K, Nishizawa Y, et al. Results of surgical treatment for sternal metastases in breast cancer. Cancer. 1987;60:2524–31.

    Article  Google Scholar 

  22. Leitlinienprogramm Onkologie, S-3 Leitlinie Brustkrebs Juli 2012. Editors: AWMF, Deutsche Krebsgesellschaft, Deutsche Krebshilfe. www.leitlinienprogramm-onkologie.de.

  23. Schalhorn A. Bronchialkarzinom: Möglichkeiten und Grenzen der Chemotherapie. Fortschr Med. 1985;103:309–11.

    PubMed  CAS  Google Scholar 

  24. Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5:119–26.

    Article  Google Scholar 

  25. Stuschke M, Heilmann HP. Lunge und Mediastinum. In: Scherer E, Sack H, editors. Strahlentherapie. Berlin: Springer; 1996.

    Google Scholar 

  26. Bülzebruck H, Danzer B, Hilkemeier G, et al. Metastasierung und Prognose des kleinzelligen Bronchialkarzinoms. Onkologe. 1998;4:1039–47.

    Article  Google Scholar 

  27. Wolf M. Kleinzelliges Bronchialkarzinom: Klinische Präsentation, Diagnostik und prognostische Faktoren. Onkologe. 1998;4:1005–18.

    Article  Google Scholar 

  28. Schalhorn A, Sunder-Plassmann L. Maligne Tumoren der Thorakal- und Mediastinalorgane. In: Wilmanns W, Huhn D, Wilms K, editors. Internistische Onkologie. Stuttgart: Thieme Verlag; 2000.

    Google Scholar 

  29. Rosell R, Lopez-Cabrerizo MP, Astudillo J. Preoperative chemotherapy for stage IIIA NSCLC. Curr Opin Oncol. 1997;9:149–55.

    Article  PubMed  CAS  Google Scholar 

  30. Albain KS, Crowley JJ, Leblanc M, Livingston RB. Determinants of improved outcome in SCLC: an analysis of the 2580-patients southwest oncology group data base. J Clin Oncol. 1990;8:1563–74.

    PubMed  CAS  Google Scholar 

  31. LeitlinieGoeckenjan G, et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie. 2010;64 Suppl 2:e1–164.

    Google Scholar 

  32. Schirrmeister H, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17(8):2381.

    PubMed  CAS  Google Scholar 

  33. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):178S–201.

    Article  PubMed  Google Scholar 

  34. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1):2122–7.

    Article  PubMed  Google Scholar 

  35. Hellwig DR, Baum P, Kirsch CM. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48:59–69.

    PubMed  CAS  Google Scholar 

  36. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17(8):2381–9.

    PubMed  CAS  Google Scholar 

  37. Reinartz P, Schaffeldt J, Sabri O, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med. 2000;27(6):721–6.

    Article  PubMed  CAS  Google Scholar 

  38. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–4.

    PubMed  CAS  Google Scholar 

  39. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.

    PubMed  Google Scholar 

  40. Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012;23(4):834–43.

    Article  PubMed  CAS  Google Scholar 

  41. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183(3):655–61.

    Article  PubMed  Google Scholar 

  42. Romer W, Nomayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47(7):1102–6.

    PubMed  Google Scholar 

  43. Helyar V, Mohan HK, Barwick T, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.

    Article  PubMed  Google Scholar 

  44. Ndlovu X, George R, Ellmann A, Warwick J. SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? J Nucl Med Commun. 2010;31(7):659–65.

    Google Scholar 

  45. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47(4):616–24.

    PubMed  Google Scholar 

  46. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, Vorreuther R, Göhring U, Schild HH, Gerhardt T, Pöge U, Ezziddin S, Biersack HJ, Ahmadzadehfar H. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2013 [Epub ahead of print].

    Google Scholar 

  47. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.

    Article  PubMed  CAS  Google Scholar 

  48. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238(1):264–271.

    Google Scholar 

  49. Strobel K, Burger C, Seifert B, Husarik DB, Soyka JD, Hany TF. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188(5):W467–474.

    Google Scholar 

  50. Zhao Z, Li L, Li F, Zhao L. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol. 2010;39(2):147–153.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Institute of Radiology and Nuclear Medicine and PET-CT Center, Johanniter Hospital, Kaiserstraße 19-21, Bonn, 53113, Germany

    Holger Palmedo MD

  2. Department of Radiology, University Hospital Bonn, Sigmund-Freud-Str. 25, Bonn, 53127, Germany

    Christian Marx MD

Authors
  1. Holger Palmedo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Marx MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Palmedo MD .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

    Hojjat Ahmadzadehfar

  2. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

    Hans-Jürgen Biersack

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Palmedo, H., Marx, C. (2014). Bone SPECT/CT in Oncology. In: Ahmadzadehfar, H., Biersack, HJ. (eds) Clinical Applications of SPECT-CT. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35283-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35283-6_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35282-9

  • Online ISBN: 978-3-642-35283-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation